Novel tissue-engineered islet transplant achieves insulin independence in type 1 diabetes

EUREKALERT
Fluorescence microscopy of islets in the omentum transplanted within the biologic scaffold. In red (insulin staining) and blue (DAPI nuclear staining). CREDIT. Diabetes Research Institute/University of Miami Miller School of Medicine
MIAMI, Florida -- Scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine have produced the first clinical results demonstrating that pancreatic islet cells transplanted within a tissue-engineered platform can successfully engraft and achieve insulin independence in type 1 diabetes. The findings, published in the May 11 issue of the New England Journal of Medicine, are part of an ongoing clinical study to test this novel strategy as an important step toward offering this life-changing cell replacement therapy to millions living with the disease.

Islet transplantation has demonstrated the ability to restore natural insulin production and eliminate severe hypoglycemia in people with type 1 diabetes. The insulin-producing cells have traditionally been implanted within the liver, but this transplant site poses some limitations for emerging applications, leading researchers to investigate other options. DRI scientists have focused on the omentum, an apron-like tissue covering abdominal organs, which is easily accessed with minimally invasive surgery and has the same blood supply and physiological drainage characteristics as the pancreas. Continue reading
__________________________________________________

You have the power to SAVE lives.  Register as an organ, eye, and tissue donor
Go to: RegisterMe.org   |   Social Media Declaration: #OrganDonor
To ensure your gift is honored, share your donation wishes with family and friends
__________________________________________________

Comments